Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 08-02-2021 | 06-30-2021 | 10-Q | |
| 2 | 05-25-2021 | 03-31-2021 | 10-Q |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga'...
Upgrades
Ladenburg Thalmann analyst Jeffrey Cohen initiates coverage on CA Healthcare Acquisition (NASDAQ:CAHC) with a Buy rating.
Revised transaction terms adjust LumiraDx’s pro forma valuation for the combined group from $5 billion to $3 billion (excludi...
It was another busy week for the SPAC market with numerous deal announcements and rumored deals. Benzinga's "SPACs Att...
LumiraDx, a UK-based provider of point-of-care diagnostics, including COVID-19 tests, has withdrawn its initial public offeri...
Gainers UTime Limited (NASDAQ: UTME) rose 39.7% to $54.50 in pre-market trading. UTime shares jumped 875% on Tuesday after ...
